Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Harvard Business School
Dow
Medtronic
AstraZeneca

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GANIRELIX ACETATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Ganirelix Acetate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00225433 ↗ Luteal Phase FSH in the IVF Poor Responder Completed University of Pennsylvania Phase 4 2005-09-01 In vitro fertilization (IVF) is a common procedure used to assist couples who have difficulty conceiving a pregnancy. IVF is a process where oocytes (eggs) are retrieved from a woman's ovaries and fertilized with sperm in the laboratory. In order to maximize the number of oocytes that can be retrieved, a women undergoes ovarian stimulation with recombinant follicle stimulating hormone (FSH). Typically 6-20 oocytes are retrieved, but in some cases there is a limited response to the stimulation, producing a limited number of oocytes. This is called poor ovarian response. This study is designed to objectively compare two treatment regimens currently advocated in clinical practice, but never compared directly. The purpose is to assess ovarian response to starting treatment at the end of the preceding cycle may increase the number of developing oocytes.
NCT00298025 ↗ A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation Completed EMD Serono Phase 4 2003-09-01 To demonstrate the comparative safety and efficacy of Cetrotide® 3 milligram (mg) and Antagon™ in the inhibition of a premature luteinizing hormone (LH) surge in women undergoing ovarian stimulation with recombinant human follicle stimulating hormone/human menopausal gonadotropin (r-hFSH/hMG) prior to assisted reproductive technology (ART) and utilizing oral contraceptives pill (OCP) for cycle programming.
NCT00734279 ↗ Follicle-Stimulating Hormone (FSH) and the Onset of Puberty Completed University of Chicago Early Phase 1 2006-03-01 The purpose of this study is to determine if the timing of the onset of puberty may be affected by FSH-regulatory peptides. We will determine how these peptides relate to FSH production in prepubertal and pubertal children by comparing the regulation of FSH control in children with precocious (early) puberty and delayed puberty. In this pilot study, we will stimulate the pubertal axis using an agonist of GnRH to determine the pubertal response of activin-A, inhibin-A and -B and follistatin. To determine baseline FSH secretion and FSH-regulatory peptide tone, we will block GnRH with a specific antagonist. These studies should lead to a better understanding of the role of FSH in controlling the onset of puberty and the pathogenesis of pubertal disorders.
NCT00734279 ↗ Follicle-Stimulating Hormone (FSH) and the Onset of Puberty Completed University of Michigan Early Phase 1 2006-03-01 The purpose of this study is to determine if the timing of the onset of puberty may be affected by FSH-regulatory peptides. We will determine how these peptides relate to FSH production in prepubertal and pubertal children by comparing the regulation of FSH control in children with precocious (early) puberty and delayed puberty. In this pilot study, we will stimulate the pubertal axis using an agonist of GnRH to determine the pubertal response of activin-A, inhibin-A and -B and follistatin. To determine baseline FSH secretion and FSH-regulatory peptide tone, we will block GnRH with a specific antagonist. These studies should lead to a better understanding of the role of FSH in controlling the onset of puberty and the pathogenesis of pubertal disorders.
NCT00734279 ↗ Follicle-Stimulating Hormone (FSH) and the Onset of Puberty Completed University of Utah Early Phase 1 2006-03-01 The purpose of this study is to determine if the timing of the onset of puberty may be affected by FSH-regulatory peptides. We will determine how these peptides relate to FSH production in prepubertal and pubertal children by comparing the regulation of FSH control in children with precocious (early) puberty and delayed puberty. In this pilot study, we will stimulate the pubertal axis using an agonist of GnRH to determine the pubertal response of activin-A, inhibin-A and -B and follistatin. To determine baseline FSH secretion and FSH-regulatory peptide tone, we will block GnRH with a specific antagonist. These studies should lead to a better understanding of the role of FSH in controlling the onset of puberty and the pathogenesis of pubertal disorders.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ganirelix Acetate

Condition Name

Condition Name for Ganirelix Acetate
Intervention Trials
Infertility 7
Fertility 2
Controlled Ovarian Stimulation 2
Delayed Puberty 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ganirelix Acetate
Intervention Trials
Infertility 9
Syndrome 2
Orthostatic Intolerance 1
Ovarian Hyperstimulation Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ganirelix Acetate

Trials by Country

Trials by Country for Ganirelix Acetate
Location Trials
United States 16
Italy 2
Czech Republic 1
Spain 1
Vietnam 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ganirelix Acetate
Location Trials
Pennsylvania 3
California 2
Connecticut 2
Wisconsin 1
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ganirelix Acetate

Clinical Trial Phase

Clinical Trial Phase for Ganirelix Acetate
Clinical Trial Phase Trials
Phase 4 9
Phase 3 1
Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ganirelix Acetate
Clinical Trial Phase Trials
Completed 15
Recruiting 2
Terminated 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ganirelix Acetate

Sponsor Name

Sponsor Name for Ganirelix Acetate
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 3
Yale University 3
Ferring Pharmaceuticals 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ganirelix Acetate
Sponsor Trials
Other 18
Industry 8
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
McKesson
Mallinckrodt
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.